
More needles in the haystack: vaccine candidates proliferate
The Intelligence from The Economist
00:00
Evaluating COVID-19 Vaccines: Novavax and Janssen
This chapter explores the development, efficacy, and distribution advantages of Novavax and Janssen COVID-19 vaccines. It highlights their effectiveness against variants, the need for global variant tracking, and logistical challenges in vaccine delivery.
Transcript
Play full episode